Article

PRMT5 inhibitors actively promote metastatic progression of lung adenocarcinoma

2026-02-02

Abstract excerpt

Epigenetic changes are a major driver of cancer progression, placing considerable focus on epigenetic regulators as therapeutic targets. Protein arginine methyltransferase 5 (PRMT5) is one such regulator, and numerous PRMT5 inhibitors (PRMT5i) in clinical trials. Despite this, the mechanisms and consequences of PRMT5i-resistance are unknown. Here, we demonstrate that aggressive cancer progression is an inbuilt fea...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a4269cde-e59c-5ef6-b2dc-e0e76ad926b4
DOI: 10.64898/2026.01.30.702866

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PRMT5 inhibitors actively promote metastatic progression of lung adenocarcinomaDOI 10.64898/2026.01.30.702866Read

Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel.Semantic proximity Read

PRMT5-exacerbating tumor stemness and immunosuppression confer a novel immunotherapeutic vulnerability in aggressive prostate cancerSemantic proximity Read

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.Semantic proximity Read

Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformationSemantic proximity Read

Another Slice of the Pie Uncovered: RIT1M90I Is an Actionable Driver in Non-Small Cell Lung Cancer.Semantic proximity Read

Protein arginine methyltransferase-5 Selective Inhibitor Enhances Therapeutic Effects of Cisplatin on Lung Cancer CellsSemantic proximity Read

Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer.Semantic proximity Read

The role of m6A methylation in targeted therapy resistance in lung cancerSemantic proximity Read

Reversible therapeutic resistance in <i>EGFR</i> mutant lung cancer caused by <i>RB1</i> loss induced lineage plasticitySemantic proximity Read

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtypeSemantic proximity Read

Designing Effective Protein Lysine and Arginine Methyltransferase Inhibitors for Chemotherapeutic TargetingSemantic proximity Read

The histone-modified landscape: Core mechanisms of osimertinib resistance in EGFR-mutant lung cancer.Semantic proximity Read